PH12019502302A1 - Anti-pd-l1 antibody and use thereof - Google Patents

Anti-pd-l1 antibody and use thereof

Info

Publication number
PH12019502302A1
PH12019502302A1 PH12019502302A PH12019502302A PH12019502302A1 PH 12019502302 A1 PH12019502302 A1 PH 12019502302A1 PH 12019502302 A PH12019502302 A PH 12019502302A PH 12019502302 A PH12019502302 A PH 12019502302A PH 12019502302 A1 PH12019502302 A1 PH 12019502302A1
Authority
PH
Philippines
Prior art keywords
antibodies
fully human
disclosed
affinity
human anti
Prior art date
Application number
PH12019502302A
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Sergei Barbashov
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Shorena Archuadze
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of PH12019502302A1 publication Critical patent/PH12019502302A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PH12019502302A 2017-04-18 2019-10-07 Anti-pd-l1 antibody and use thereof PH12019502302A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
PH12019502302A1 true PH12019502302A1 (en) 2020-09-21

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502302A PH12019502302A1 (en) 2017-04-18 2019-10-07 Anti-pd-l1 antibody and use thereof

Country Status (17)

Country Link
US (1) US20210115143A1 (https=)
EP (1) EP3612565A4 (https=)
JP (2) JP2020517239A (https=)
KR (1) KR102323960B1 (https=)
CN (1) CN110856446A (https=)
AU (1) AU2018256392B2 (https=)
BR (1) BR112019021828B1 (https=)
CA (1) CA3059447A1 (https=)
CL (1) CL2019002953A1 (https=)
CO (1) CO2019012118A2 (https=)
EA (1) EA201900443A1 (https=)
MA (1) MA50038A (https=)
MX (1) MX2019012461A (https=)
MY (1) MY199319A (https=)
PH (1) PH12019502302A1 (https=)
SG (1) SG11201909041SA (https=)
WO (1) WO2018195226A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709B (zh) * 2019-04-11 2024-08-23 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
EP3833691B1 (en) * 2019-04-26 2024-09-25 I-Mab Biopharma Co., Ltd. Human pd-l1 antibodies
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CN116178545B (zh) * 2021-09-24 2025-09-12 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2015061668A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2940242C (en) * 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN117088979A (zh) * 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Also Published As

Publication number Publication date
EP3612565A4 (en) 2021-06-16
EA201900443A1 (ru) 2020-03-06
MA50038A (fr) 2020-07-08
MX2019012461A (es) 2019-12-11
JP2020517239A (ja) 2020-06-18
KR20190141169A (ko) 2019-12-23
JP2023025003A (ja) 2023-02-21
SG11201909041SA (en) 2019-11-28
BR112019021828B1 (pt) 2022-09-20
MY199319A (en) 2023-10-24
KR102323960B1 (ko) 2021-11-10
AU2018256392B2 (en) 2024-05-16
CO2019012118A2 (es) 2020-04-01
BR112019021828A2 (pt) 2020-03-24
WO2018195226A1 (en) 2018-10-25
CA3059447A1 (en) 2018-10-25
CN110856446A (zh) 2020-02-28
AU2018256392A1 (en) 2019-10-17
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
SA523442262B1 (ar) أجسام مضادة للارتباط بـ cd3
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2024005027A (es) Anticuerpos de union a cd3.
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
EA201491700A1 (ru) Человеческие антитела к cd27, методы и применение
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
MX2024008109A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
MY187325A (en) Anti-5t4 antibodies and antibody-drug conjugates
MY202157A (en) Anti-pd-l1 antibody and use thereof
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
WO2020168231A3 (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
NZ602515A (en) Proteins that bind pi16 and uses thereof
WO2017160699A3 (en) Method of preventing graft versus host disease
PH12022550765A1 (en) Binding molecule specific for lif and use thereof
MY187583A (en) Igf-1r antibody and its use for the diagnosis of cancer